SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s gets 13 USFDA observations for Visakhapatnam facility

09 Mar 2017 Evaluate

Dr. Reddy’s Laboratories’ formulation manufacturing facility at Duvvada, Visakhapatnam, has been audited by the US Food and Drug Administration (USFDA), and the audit has been completed on March 8, 2017. The company has been issued a Form 483 with 13 observations, which it is addressing.

Earlier, the company’s API manufacturing plant at Miryalaguda, had been audited by the USFDA and the audit had been completed on February 21, 2017. The company had been issued a Form 483 with three observations, which it was addressing.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.



Dr. Reddys Lab Share Price

1293.25 -13.55 (-1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×